Arvinas (ARVN) Retained Earnings (2017 - 2026)
Arvinas (ARVN) posted quarterly Retained Earnings of $2.1 billion for Q1 2026, up 143166.67% year-over-year from N/an in Q1 2025, and up 178983.33% quarter-over-quarter from $1.2 million in Q4 2025.
Arvinas (ARVN) Retained Earnings (2017 - 2026) Analysis & Trends
Arvinas' Retained Earnings history runs 10 years deep, the most recent figure standing at $2.1 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 143166.67% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 143166.67% YoY), while the FY2025 annual figure was $1.2 million, up 100.08% from the prior year.
- Retained Earnings for Q1 2026 stood at $2.1 billion, up from $1.2 million in the prior quarter.
- The five-year high for Retained Earnings was $2.1 billion in Q1 2026, with the low at -$1.5 billion in Q4 2024.
- The 5-year median for Retained Earnings is $1.2 million (2025), against an average of $337.7 million.
- Peak annual rise in Retained Earnings reached 310205.56% in 2022, while the deepest fall reached 317.39% in 2022.
- Arvinas' Retained Earnings stood at -$19.2 million in 2022, then surged by 10494.27% to $2.0 billion in 2023, then slumped by 176.75% to -$1.5 billion in 2024, then surged by 100.08% to $1.2 million in 2025, then soared by 178983.33% to $2.1 billion in 2026.
- Business Quant data shows ARVN's Retained Earnings at $2.1 billion in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 2.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.16 Bn |
| Mar 31, 2026 | 2.15 Bn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 2.12 Bn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | -1.53 Bn |
| Sep 30, 2024 | 2.07 Bn |
| Jun 30, 2024 | -1.44 Bn |
| Mar 31, 2024 | -4.40 Mn |
| Dec 31, 2023 | 2.00 Bn |
| Sep 30, 2023 | 1.64 Bn |
| Jun 30, 2023 | -1.11 Bn |
| Mar 31, 2023 | -12.60 Mn |
| Dec 31, 2022 | -19.20 Mn |
| Sep 30, 2022 | -882.50 Mn |
| Jun 30, 2022 | 1.51 Bn |
| Mar 31, 2022 | -746.30 Mn |
| Dec 31, 2021 | -4.60 Mn |
| Sep 30, 2021 | 1.45 Bn |